Optafenac0.1%

Optafenac ophthalmic suspension is a nonsteroidal anti-inflammatory drug (NSAID) used in and around the eye. Its approved and evidence-based uses are:

• Established/FDA-approved use: Treatment of pain and inflammation associated with cataract surgery.
• Formulation-specific approved use: Certain higher-strength formulations of Optafenac (0.3%) are also approved for reduction of the risk of postoperative macular edema associated with cataract surgery, particularly in patients with diabetes mellitus.

Optafenac is intended strictly for short-term perioperative use as directed by an ophthalmologist and is not indicated for chronic or unsupervised long-term use.

Each mL of Nepafenac ophthalmic suspension typically contains Nepafenac 1 mg (0.1% w/v) or 3 mg (0.3% w/v), depending on the specific product strength, along with ophthalmic-grade suspending agents, preservative (commonly benzalkonium chloride), and pH-adjusting/tonicity agents in purified water. Strength and exact excipients vary by manufacturer; check the product label/pack insert for the exact formulation dispensed.

Optafenac is a topical ophthalmic nonsteroidal anti-inflammatory prodrug used to control ocular pain and inflammation following cataract surgery. After instillation, Optafenac penetrates the cornea and is converted by intraocular tissue enzymes into its active metabolite, which inhibits prostaglandin synthesis. Optafenac is supplied as a sterile ophthalmic suspension for topical application to the eye and is used under ophthalmologist supervision as part of the perioperative care of cataract surgery patients.

Ophthalmic Nonsteroidal Anti-Inflammatory Drug (NSAID) — Optafenac is classified as a topical ocular anti-inflammatory/analgesic agent used in ophthalmic surgical care.

Nepafenac is a nonsteroidal anti-inflammatory prodrug. Following topical ocular administration, it penetrates the cornea and is converted by intraocular hydrolases (present in ocular tissues such as the cornea and iris/ciliary body) into amfenac, an NSAID that potently inhibits cyclooxygenase (COX-1 and COX-2). This inhibition blocks the synthesis of prostaglandins, which are key mediators of ocular inflammation, pain, vasodilation, and increased vascular permeability associated with surgical trauma to the eye.

By suppressing prostaglandin-mediated inflammation, Nepafenac reduces postoperative pain, ocular inflammation, and (for the higher-strength formulation) the risk of postoperative macular edema following cataract surgery. Systemic absorption after ophthalmic dosing is minimal.

For ophthalmic (eye drop) use only — not for injection, oral, or systemic use.

• Shake the bottle well before each use if the product is a suspension.
• Wash hands before use.
• Tilt the head back, gently pull down the lower eyelid to form a small pocket, and instill one drop into the pocket without letting the dropper tip touch the eye, eyelid, or any other surface.
• Close the eye gently and apply light pressure at the inner corner of the eye (near the nose) for about 1–2 minutes to reduce systemic absorption.
• If more than one eye drop medicine is being used, wait at least 5 minutes between different eye drop products.
• Remove contact lenses before instillation; contact lens use is generally not recommended during the Optafenac treatment course after cataract surgery.

Because Optafenac is applied topically to the eye, systemic drug interactions are minimal. However, clinically relevant local (ocular) interactions include:

• Other topical ophthalmic NSAIDs or corticosteroids: Concomitant use with other topical NSAIDs may increase the risk of corneal healing problems and should generally be avoided unless specifically directed by the ophthalmologist.
• Systemic anticoagulants or antiplatelet agents (e.g., warfarin, aspirin): May theoretically add to a bleeding tendency at the ocular surface, particularly in patients with corneal epithelial defects; use with caution and closer monitoring in such patients.

Inform the treating physician of all other eye drops and systemic medications being used before starting Optafenac.

Most side effects of Optafenac are local, mild, and transient. Reported adverse effects include:

• Common: Eye pain or discomfort, foreign body sensation, sticky sensation in the eye, blurred or decreased vision, eye redness (conjunctival/ocular hyperemia), tearing, itching, dry eye, capsular opacity.
• Less common: Increased intraocular pressure, corneal edema, iritis (anterior chamber inflammation).
• Rare but serious: Keratitis, corneal epithelial breakdown, corneal thinning, erosion, or (very rarely) corneal perforation, especially with prolonged or inappropriate use; delayed or slowed corneal wound healing.

Patients should seek prompt medical attention if there is worsening eye pain, redness, marked change in vision, or the eye drops appear to make symptoms worse rather than better.

Pregnancy: Optafenac should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use. Although systemic absorption after ophthalmic administration is minimal, NSAIDs as a class are associated with risks to the fetus (including premature closure of the ductus arteriosus) when used systemically, particularly in the third trimester, so caution is warranted.

Lactation: It is not known whether Optafenac is excreted in human breast milk in clinically significant amounts. Caution should be exercised, and a physician should be consulted before use of Optafenac while breastfeeding.

Corneal effects: Topical NSAIDs such as Optafenac may slow or delay corneal healing. Use with caution in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye), rheumatoid arthritis, or repeat ocular surgeries within a short period, as these patients are at increased risk of corneal adverse events, including rare cases of corneal thinning, erosion, ulceration, or perforation. Discontinue Optafenac and seek prompt ophthalmic evaluation if corneal epithelial breakdown occurs.

Cross-sensitivity: There is a potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs; use caution in patients with a history of aspirin-sensitive asthma (see Contraindications).

Duration of use: Optafenac is intended for short-term perioperative use only, exactly as prescribed; do not continue use beyond the course directed by the ophthalmologist.

Contact lenses: Contact lens wear is generally not recommended during the postoperative Optafenac treatment period.

Increased bleeding tendency: Some NSAIDs may prolong bleeding time of ocular tissue due to interference with platelet aggregation; caution is warranted in patients on concurrent anticoagulant/antiplatelet therapy (see Interactions).

Ocular overdose (e.g., excessive/accidental instillation) is unlikely to cause significant systemic toxicity but may cause increased local irritation. If Optafenac is accidentally ingested or a significantly excessive amount is instilled in the eye, seek immediate medical attention or contact a poison control center/emergency services. Do not attempt unsupervised home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Shake well before each use if the product is a suspension. Keep the bottle tightly closed and keep out of reach of children.

Pediatric patients: The safety and efficacy of Optafenac have not been well established in the pediatric population; use only under close ophthalmologist supervision if prescribed in children.

Elderly patients: No overall differences in safety or effectiveness of Optafenac have been observed between elderly and younger adult patients; standard adult dosing applies.

Renal/hepatic impairment: No specific dose adjustment has been established; systemic absorption is minimal with ophthalmic use, but use should still be under physician guidance in patients with significant organ impairment.

Diabetic patients: Patients with diabetes mellitus are at increased risk of corneal adverse events with topical NSAIDs including Optafenac; close monitoring is advised (see Precautions and Warnings).

Optafenac is used for a defined short perioperative course related to cataract surgery — typically starting one day before surgery and continuing through the first two weeks after surgery (or, for the risk-reduction indication in certain formulations, up to about 60 days in diabetic patients at the ophthalmologist's discretion). Treatment duration must follow the exact prescription; do not use Optafenac for longer than directed by the treating physician.

Nepafenac belongs to the ophthalmic nonsteroidal anti-inflammatory drug (NSAID) class, specifically a topical ocular NSAID prodrug used in ophthalmic surgical care.

Nepafenac is a prodrug that, after penetrating the cornea, is converted by ocular tissue hydrolases into amfenac, an active NSAID. Amfenac inhibits both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, blocking the conversion of arachidonic acid to prostaglandins. Since prostaglandins mediate ocular inflammatory responses (including vasodilation, increased vascular permeability, and sensitization of pain receptors) following surgical trauma, this inhibition by Nepafenac reduces postoperative pain, inflammation, and the associated risk of macular edema.

C (legacy FDA pregnancy category; use only if clearly needed, with physician guidance)

The safety and effectiveness of Optafenac in pediatric patients have not been well established through controlled clinical trials. Optafenac should be used in children only if specifically prescribed and closely supervised by an ophthalmologist, who will weigh the potential benefits against the limited pediatric safety data.